Device Trial Radar · NCT00519961
A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery
Last checked: Nov 20, 2026Latest source record: Mar 16, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,800
Planned (sponsor's estimate)
Start
Feb 2007
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- Hoffmann-La RocheNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 23, 2007
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to validate the screening potential of NT-proBNP for the identification of patients scheduled for vascular surgery who would benefit from additional pre-operative cardiac testing. All patients will have NT-proBNP concentrations measured pre-operatively. For low-intermediate risk patients only those with abnormal values will receive further cardiac testing; all high risk patients will be referred for additional testing.
Conditions
- Peripheral Vascular Disease
Interventions
Elecsys®proBNPDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Collection of 30-day and 1-year postoperative cardiac eventsTime frame: 30-day and 1-year postoperation
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Dublin, Ireland · Recruiting
Site not named
Rotterdam, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.